<code id='464B659DE7'></code><style id='464B659DE7'></style>
    • <acronym id='464B659DE7'></acronym>
      <center id='464B659DE7'><center id='464B659DE7'><tfoot id='464B659DE7'></tfoot></center><abbr id='464B659DE7'><dir id='464B659DE7'><tfoot id='464B659DE7'></tfoot><noframes id='464B659DE7'>

    • <optgroup id='464B659DE7'><strike id='464B659DE7'><sup id='464B659DE7'></sup></strike><code id='464B659DE7'></code></optgroup>
        1. <b id='464B659DE7'><label id='464B659DE7'><select id='464B659DE7'><dt id='464B659DE7'><span id='464B659DE7'></span></dt></select></label></b><u id='464B659DE7'></u>
          <i id='464B659DE7'><strike id='464B659DE7'><tt id='464B659DE7'><pre id='464B659DE7'></pre></tt></strike></i>

          Home / explore / comprehensive

          comprehensive


          comprehensive

          author:comprehensive    Page View:57

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In